Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value
$18.75+0.61 (+3.36%)
Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –
Acadia Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Acadia Pharmaceuticals's enterprise value was $2.21B on Nov 11, 2026, against $3.39B a year earlier. Over the last 5 years it ranged from $1.68B to $4.79B, with a median of $2.92B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.21B | -39.9% |
| 2025 | Dec 31, 2025 | $3.67B | +47.6% |
| 2024 | Dec 31, 2024 | $2.49B | -48.1% |
| 2023 | Dec 29, 2023 | $4.79B | +123.7% |
| 2022 | Dec 30, 2022 | $2.14B | -33.3% |
| 2021 | Dec 31, 2021 | $3.21B | -59.1% |
| 2020 | Dec 31, 2020 | $7.85B | +33.4% |
| 2019 | Dec 31, 2019 | $5.88B | +225.6% |
| 2018 | Dec 31, 2018 | $1.81B | -45.7% |
| 2017 | Dec 29, 2017 | $3.33B | +14.6% |
| 2016 | Dec 30, 2016 | $2.90B | -13.5% |
| 2015 | Dec 31, 2015 | $3.36B | +18.7% |
| 2014 | Dec 31, 2014 | $2.83B | +39.5% |
| 2013 | Dec 31, 2013 | $2.03B | +694.6% |
| 2012 | Dec 31, 2012 | $255.12M | +1120.0% |
| 2011 | Dec 30, 2011 | $20.91M | -22.1% |
| 2010 | Dec 31, 2010 | $26.85M | – |
See a number that looks wrong?